G protein-coupled receptor

κ-opioid receptor

Kappa opioid receptor

The κ-opioid receptor was cloned from mouse brain together with the δ receptor, during a search for somatostatin receptors. Both couple to G proteins and inhibit the formation of cyclic AMP.1

Antibodies against the cloned receptor stained perikarya and fibres in the deep layers of the cortex, the central and medial amygdala, the bed nucleus of the stria terminalis, the nucleus accumbens, the olfactory tubercle, the claustrum, hypothalamic nuclei, the median eminence, the central gray, the dorsal raphe, the substantia nigra pars reticulata, the ventral tegmental area, the spinal cord and the dorsal root ganglia, and also the neural and intermediate lobes of the pituitary. The staining agreed well with earlier maps of the mRNA and of the binding. Kappa binding is less widespread than mu binding and was dense in the amygdala, olfactory tubercle, nucleus accumbens, caudate putamen, medial preoptic area, hypothalamus, median eminence, periventricular thalamus and interpeduncular nucleus.2,3

In mice lacking the receptor, the other components of the opioid system and the spontaneous activity are not changed, but the mice are more sensitive to chemical visceral pain. The hypolocomotor, analgesic and aversive actions of the kappa agonist U-50,488H depend on the receptor. It does not contribute to morphine analgesia and reward, but it takes part in the expression of morphine abstinence.4

The receptor activates pertussis toxin-sensitive Gi/o proteins, which inhibit adenylyl cyclase and release G beta-gamma, and G beta-gamma modulates calcium and potassium channels. Agonists also activate kinase cascades, among them GRKs and the MAP kinases ERK1/2, p38 and JNK. A review reports that ligand-induced conformations which evoke beta-arrestin-dependent p38 activation result in aversion, whereas conformations that activate JNK without arrestin produce a long-lasting inactivation of the receptor. The authors put forward that partial agonists which do not efficiently activate p38 may be analgesics without the dysphoric or hallucinogenic effects of highly efficacious agonists, and that antagonists which do not activate JNK may promote stress resilience.5

In men, the κ agonist MR 2033 caused dose-dependent dysphoria and psychotomimetic effects, and naloxone blocked them.6 In mice, repeated forced swim and inescapable footshock produced aversive behaviour that was blocked by a KOR antagonist and absent in mice lacking dynorphin. Injection of corticotropin-releasing factor or urocortin III produced place aversion that was blocked by deletion of the dynorphin gene or by KOR antagonism. The authors conclude that the aversive effects of stress are mediated by CRF2 receptor stimulation of dynorphin release and the subsequent activation of the KOR. Stress and CRF caused dynorphin-dependent KOR activation in the basolateral amygdala, the nucleus accumbens, the dorsal raphe and the hippocampus.7 Salvinorin A, the main active compound of Salvia divinorum, is a potent and selective agonist at this receptor. It showed no activity at 50 other receptors, transporters and ion channels, including the 5-HT2A receptor of the classic hallucinogens, and it is the first known natural agonist of an opioid receptor subtype without a nitrogen atom.8 In a double-blind study with four volunteers, the effects of inhaled salvinorin A peaked at the first measurement after two minutes and were gone after about 20 minutes.9

Sources (9)
  1. Yasuda et al. 1993Yasuda K, Raynor K, Kong H, et al. (1993) Cloning and functional comparison of kappa and delta opioid receptors from mouse brain Proc Natl Acad Sci U S A
  2. Mansour et al. 1996Mansour A, Burke S, Pavlic RJ, et al. (1996) Immunohistochemical localization of the cloned kappa 1 receptor in the rat CNS and pituitary Neuroscience
  3. Mansour et al. 1987Mansour A, Khachaturian H, Lewis ME, et al. (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain J Neurosci
  4. Simonin et al. 1998Simonin F, Valverde O, Smadja C, et al. (1998) Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal EMBO J
  5. Bruchas et al. 2010Bruchas MR, Chavkin C (2010) Kinase cascades and ligand-directed signaling at the kappa opioid receptor Psychopharmacology (Berl)
  6. Pfeiffer et al. 1986Pfeiffer A, Brantl V, Herz A, et al. (1986) Psychotomimesis mediated by kappa opiate receptors Science
  7. Land et al. 2008Land BB, Bruchas MR, Lemos JC, et al. (2008) The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system J Neurosci
  8. Roth et al. 2002Roth BL, Baner K, Westkaemper R, et al. (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist Proc Natl Acad Sci U S A
  9. Johnson et al. 2011Johnson MW, MacLean KA, Reissig CJ, et al. (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum Drug Alcohol Depend

Binding affinity (Kᵢ)

16 substances, 22 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

11 measurements
  • BuprenorphineAgonistdepends on assay0.11 nMHuang et al. 2001 · 3 reports
    Assay
    recombinant human KOR in CHO membranes, [3H]diprenorphine competition
    Shown value from
    Huang et al. 2001, Table 1
    Range
    0.11–1.3 nM in 3 reports
    Error
    ± 0.05 SEM, n = 4

    Values depend on the assay, species or conditions, and each is valid only for its own. 3 reports in all, 0.11–1.3 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Huang et al. 20010.11 nMTable 1
    Toll et al. 19980.80 nMTable 5
    Obeng et al. 20211.3 nMTable 2
  • Hydromorphone2.8 nMWentland et al. 2009
    Assay
    CHO cell membranes expressing the human KOR, [3H]U69,593 displacement
    Shown value from
    Wentland et al. 2009, Table 1
  • Salvinorin AAgonistunresolved16 nMRoth et al. 2002 · 3 reports
    Assay
    HEK293 cells expressing cloned human KOR, [3H]bremazocine displacement
    Shown value from
    Roth et al. 2002, Table 1
    Range
    1.3–19 nM in 3 reports

    Reported values disagree and no value is established. 4 reports in all, 1.3–19 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Roth et al. 200216 nMTable 1
    Chavkin et al. 200419 nMTable 2
    Béguin et al. 20051.3 nMTable 1 (text)
  • MorphineAgonist24 nMNeumeyer et al. 2012 · 3 reports
    Assay
    CHO cells expressing human KOR, [3H]U69,593 competition
    Shown value from
    Neumeyer et al. 2012, Table 2
    Range
    24–47 nM in 3 reports
    Error
    ± 2.3 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Neumeyer et al. 201224 nMTable 2
    Toll et al. 199847 nMTable 5
    Obeng et al. 202140 nMTable 2
  • FentanylAgonist85 nMToll et al. 1998 · 2 reports
    Assay
    human KOR in CHO cells, [3H]U69,593 competition
    Shown value from
    Toll et al. 1998, Table 5
    Range
    85–202 nM in 2 reports
    Error
    ± 19 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Toll et al. 199885 nMTable 5
    Obeng et al. 2021202 nMTable 2
  • 7-Hydroxymitragynine188 nMKruegel et al. 2016 · 2 reports
    Assay
    cells expressing human KOR, opioid receptor binding
    Shown value from
    Kruegel et al. 2016, Table 2
    Range
    188–220 nM in 2 reports
    Error
    ± 38 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Obeng et al. 2021220 nMTable 2
    Kruegel et al. 2016188 nMTable 2
  • HydrocodoneAgonist260 nMNeumeyer et al. 2012
    Assay
    CHO cells expressing human KOR, [3H]U69,593 competition
    Shown value from
    Neumeyer et al. 2012, Table 2
    Error
    ± 9.7 SEM
  • MethadoneAgonist324 nMToll et al. 1998
    Assay
    human KOR in CHO cells, [3H]U69,593 competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 18 SD
  • Mitragynine772 nMKruegel et al. 2016 · 2 reports
    Assay
    cells expressing human KOR, opioid receptor binding
    Shown value from
    Kruegel et al. 2016, Table 2
    Range
    772–1700 nM in 2 reports
    Error
    ± 207 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Obeng et al. 20211700 nMTable 2
    Kruegel et al. 2016772 nMTable 2
  • Psilocin2000 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • Ibogaine3680 nMMaillet et al. 2015
    Assay
    cells expressing human kappa opioid receptor, radioligand binding
    Shown value from
    Maillet et al. 2015, Results
    Error
    ± 220 SEM

Guinea pig

6 measurements
  • BuprenorphineAgonist1.5 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]U69,593 competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 0.25 SD
  • Salvinorin AAgonist4.3 nMRoth et al. 2002
    Assay
    guinea pig brain membranes, [3H]bremazocine displacement (native KOR)
    Shown value from
    Roth et al. 2002, Table 1
  • OxymorphoneAgonist62 nMBen Haddou et al. 2014
    Assay
    native guinea pig brain membranes, [3H]U69,593 competition
    Shown value from
    Ben Haddou et al. 2014, Table 1
    Error
    ± 1.2 SEM
  • MorphineAgonistunresolved113 nMBen Haddou et al. 2014 · 2 reports
    Assay
    native guinea pig brain membranes, [3H]U69,593 competition
    Shown value from
    Ben Haddou et al. 2014, Table 1
    Range
    34–113 nM in 2 reports
    Error
    ± 9.0 SEM

    Reported values disagree and no value is established. 2 reports in all, 34–113 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Ben Haddou et al. 2014113 nMTable 1
    Toll et al. 199834 nMTable 5
  • FentanylAgonist151 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]U69,593 competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 5.2 SD
  • MethadoneAgonist728 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]U69,593 competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 120 SD

Rat

4 measurements
  • 3-HO-PCP140 nMItzhak et al. 1981
    Assay
    rat brain homogenate (minus cerebellum), [3H]ethylketocyclazocine 1.5 nM, kappa site
    Shown value from
    Itzhak et al. 1981, Table 1B
  • Oxycodone677 nMMonory et al. 1999
    Assay
    rat brain membranes, displacement of [3H]U69,593
    Shown value from
    Monory et al. 1999, Table II
  • TapentadolAgonist910 nMTzschentke et al. 2007
    Assay
    rat opioid receptor binding assay
    Shown value from
    Tzschentke et al. 2007, Table 1
    Error
    ± 90 SEM
  • PCP4100 nMItzhak et al. 1981
    Assay
    rat brain homogenate (minus cerebellum), [3H]ethylketocyclazocine 1.5 nM, kappa site
    Shown value from
    Itzhak et al. 1981, Table 1B

Unspecified

1 measurement
  • Mitragyninesource not traced455 nMLydecker et al. 2016
    Assay
    KOR opioid receptor binding, quoted in a review table (original assay not restated)
    Shown value from
    Lydecker et al. 2016, Table 1

Functional potency (EC₅₀)

6 substances, 6 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

6 measurements
  • BuprenorphineAgonist0.04 nMHuang et al. 2001
    Assay
    recombinant human KOR in CHO membranes, [35S]GTPgammaS functional assay
    Shown value from
    Huang et al. 2001, Table 2
    Error
    ± 0.01 SEM
    Emax
    10.0 ± 4.0%
  • Salvinorin AAgonistdepends on assay69 nMChavkin et al. 2004
    Assay
    Xenopus oocytes expressing KOR and Kir3.1/3.2, inward K+ current
    Shown value from
    Chavkin et al. 2004, Results, Fig. 4

    Values depend on the assay, species or conditions, and each is valid only for its own. 3 reports in all, 0.63–69 nM.

  • OxymorphoneAgonist463 nMBen Haddou et al. 2014
    Assay
    CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
    Shown value from
    Ben Haddou et al. 2014, Table 2
    Error
    ± 116 SEM
    Emax
    48.0 ± 11.0%
  • MorphineAgonistdepends on assay710 nMBen Haddou et al. 2014 · 2 reports
    Assay
    CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
    Shown value from
    Ben Haddou et al. 2014, Table 2
    Range
    484–710 nM in 2 reports
    Error
    ± 23 SEM
    Emax
    76.1 ± 2.0%

    Values depend on the assay, species or conditions, and each is valid only for its own. 3 reports in all, 484–2185 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Ben Haddou et al. 2014710 nMTable 2
    Toll et al. 1998484 nMTable 7
  • FentanylAgonist2368 nMToll et al. 1998
    Assay
    human KOR-CHO cell membranes, [35S]GTPgammaS binding
    Shown value from
    Toll et al. 1998, Table 7
    Error
    ± 534 SD
    Emax
    30.0 ± 4.0%
  • MethadoneAgonist4943 nMToll et al. 1998
    Assay
    human KOR-CHO cell membranes, [35S]GTPgammaS binding
    Shown value from
    Toll et al. 1998, Table 7
    Error
    ± 400 SD
    Emax
    25.0 ± 16.0%

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.